Close

Pacira Pharma (PCRX) Announces FDA Approval of Supplemental New Drug Application for EXPAREL in Pediatric Patients

Go back to Pacira Pharma (PCRX) Announces FDA Approval of Supplemental New Drug Application for EXPAREL in Pediatric Patients

Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® (bupivacaine liposome injectable suspension) in Pediatric Patients

March 22, 2021 6:43 PM EDT

-- EXPAREL is the first and only FDA-approved long-acting local analgesic for children aged six and over
-- Conference call tomorrow at 8:30 a.m. ET --

PARSIPPANY, N.J., March 22, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and Drug Administration (FDA) has approved the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL label to include use in patients 6 years of age and older for... More